Cardiac MRI for Trastuzumab Induced Cardiomyopathy
Author Information
Author(s): Fallah-Rad Nazanin, Lytwyn Matthew, Fang Tielan, Kirkpatrick Iain, Jassal Davinder S
Primary Institution: Institute of Cardiovascular Sciences, St. Boniface Research Centre, University of Manitoba
Hypothesis
What is the utility of cardiac magnetic resonance imaging in assessing trastuzumab induced cardiomyopathy?
Conclusion
Late gadolinium enhancement using CMR is a novel way of detecting early changes in the myocardium due to trastuzumab induced cardiotoxicity.
Supporting Evidence
- All 10 patients showed subepicardial linear late gadolinium enhancement in the lateral portion of the left ventricles.
- The mean left ventricular ejection fraction (LVEF) at diagnosis was 29 ± 4%.
- Six patients recovered normal LVEF after discontinuation of trastuzumab.
Takeaway
Doctors used a special heart scan to see how a cancer drug affected the hearts of some patients, and they found signs of heart damage in all of them.
Methodology
The study involved 10 breast cancer patients with trastuzumab induced cardiomyopathy who underwent cardiac MRI to assess heart function and detect late gadolinium enhancement.
Limitations
The study is limited by the small number of patients.
Participant Demographics
Mean age of participants was 40 years, with a range from 27 to 56 years.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website